|
|
|
|
By optimizing factors like plasmid design, yield, analytics, and production pathways early—and considering downstream needs such as the final regulatory package—drug developers can prevent problems, reduce rework, and keep development on schedule.
|
|
|
|
|
Hear the extraordinary story of how one family, driven by urgency and guided by pioneering leaders in gene therapy, partnered with AAV experts to develop a treatment for their daughter’s ultra-rare neurodegenerative disorder, NEDAMSS, in just 14 months.
|
|
|
|
|
Strong analytics and process validation are vital for advanced therapies. Expert AAV partners help reduce variability and risk. Discover key steps to advance your AAV therapy from concept to commercialization.
|
|
|
|
|
Inadequate preclinical planning and process development can stall advanced therapy programs, delaying treatments for serious diseases. Leveraging an experienced partner to optimize AAV processes with DoE is essential to reduce variability and risk.
|
|
|
